Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova最新文献

{"title":"[Honored Scientist of the RSFSR Professor Vladimir Semenovich Lobzin (1924-1993).]","authors":"V V Goldobin, V Yu Lobzin, N M Zhulev","doi":"10.17116/jnevro2025125021122","DOIUrl":"10.17116/jnevro2025125021122","url":null,"abstract":"<p><p>Prof. V.S. Lobzin occupies a special honorable place among the neurologists of Leningrad-St. Petersburg. He can be rightfully referred to the leading neurologists of our country. Vladimir Semenovich's scientific interests were wide and multifaceted, due to his rich clinical experience, many years of practical work in medical and educational institutions, including medical, scientific and teaching activities at the Kirov Military Medical Academy and Lenin Medical Academy. He is a member of the S.M. Kirov Military Medical Academy and the S.M. Kirov Leningrad State Institute for Advanced Training of Doctors. S.M. Kirov. He made a significant scientific contribution to various sections of clinical neurology and created a scientific school. For all those who came in contact with Vladimir Semyonovich on the most diverse issues of neurology, he was fully a teacher who generously passed on his knowledge and rich experience to the people around him.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"125 2","pages":"122"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143569032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Autoimmune diseases of central nervous system and respiratory viral infections in children].","authors":"N V Skripchenko, G F Zheleznikova, L A Alekseeva, T V Bessonova, P S Verbenko, E Yu Skripchenko","doi":"10.17116/jnevro202512501139","DOIUrl":"10.17116/jnevro202512501139","url":null,"abstract":"<p><p>Foreign data about the role of influenza virus, measles and SARS-CoV-2 in the development of autoimmune diseases is described. The main characteristics of most frequent autoimmune diseases is given. The authors give characteristics of influenza virus, measles and SARS-CoV-2 virus as infectious agents- triggers of autoimmune central nervous system diseases. Modern possibilities to strenghen a patogenic therapy by Cytoflavin, which has a complex effect aimed at improving metabolic processes in the brain, are presented.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"125 1","pages":"39-46"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A case of Becker muscular dystrophy in a woman with skewed X-chromosome inactivation].","authors":"D G Korotkova, M I Karpova, K Yu Galiulina, A F Vasilenko, M V Shestakova, T N Kashko, G V Buyanova","doi":"10.17116/jnevro2025125011139","DOIUrl":"10.17116/jnevro2025125011139","url":null,"abstract":"<p><p>The article presents a rare case of Becker muscular dystrophy symptoms development in a female patient manifested by weakness in the muscles of the lower limbs in youth. The diagnosis was established based on clinical symptoms, molecular-genetic testing, electromyography data, magnetic resonance imaging of the lower limb muscles, and blood creatine phosphokinase activity. DNA analysis using the next-generation sequencing «Large neurological panel» (Genomed laboratory, Moscow) yielded data supporting the presence of a deletion of the X chromosome segment with approximate boundaries 31323344-32809866 and a size of 1.486.522 bp, encompassing regions of the OMIM-annotated <i>DMD</i> gene. Multiplex ligation-dependent probe amplification (MLPA) using commercial kits SALSA MLPA Probemix P034-DMDI and P035-DMD2 (MRC-Holland) was performed to search for deletions/duplications of exons 1-79 of the DMD gene. As a result of the analysis, a deletion of exons 7-62 of the DMD gene in a heterozygous state was identified. Thus, the presence of the deletion was confirmed by the reference method. DNA analysis was conducted to detect skewed X-chromosome inactivation. The results show an 87%:13% ratio, indicating skewed (non-random) X-chromosome inactivation (repeats count 24/26).</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"125 1","pages":"139-144"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Sleep deprivation and the development of oxidative stress in animal models].","authors":"O P Bukareva, O N Pavlova, D S Gromova, A V Zakharov, I V Shirolapov","doi":"10.17116/jnevro2025125031124","DOIUrl":"https://doi.org/10.17116/jnevro2025125031124","url":null,"abstract":"<p><strong>Objective: </strong>To study the features and mechanisms of development of oxidative stress in animal models during sleep deprivation.</p><p><strong>Material and methods: </strong>The experiments were carried out on 6-month-old male rats (<i>n</i>=60), which were divided equally into 3 groups. Group 1 included intact animals, groups 2 and 3 were subjected to modeling of chronic sleep deprivation using the method of cyclic sleep restriction. Animals of group 3, in addition to the standard diet, received resveratrol (10 mg/kg, intragastric) daily. On days 0, 1, 3 and 5 of the experiment, the activity of antioxidant enzymes and the concentration of peroxidation products in the blood serum was assessed.</p><p><strong>Results: </strong>Sleep deprivation in animal models causes an intensification of oxidative processes (increased concentrations of malondialdehyde and diene conjugates) and a decrease in the activity of antioxidant enzymes (catalase, superoxide dismutase, glutathione peroxidase, glutathione reductase).</p><p><strong>Conclusion: </strong>Sleep deprivation contributes to the accumulation of highly toxic products of lipid peroxidation in the body tissues, which is reflected in metabolic disorders, and a decrease in adaptive capabilities. Additional administration of resveratrol helps to reduce the amplitude of fluctuations in redox balance, which can be considered as a possible way to correct oxidative stress and prevent disorders associated with sleep restriction and dysregulation of the sleep-wake cycle.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"125 3","pages":"124-129"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143804931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A comprehensive study of Alzheimer's disease biomarkers in plasma and cerebrospinal fluid].","authors":"A K Minochkin, V Yu Lobzin, A Yu Emelin, Yu P Kopteva, O A Klitsenko, S V Apalko, S G Sherbak","doi":"10.17116/jnevro202512504243","DOIUrl":"https://doi.org/10.17116/jnevro202512504243","url":null,"abstract":"<p><strong>Objective: </strong>To determine, evaluate, and analyze the diagnostic value of various laboratory biomarkers of Alzheimer's disease (AD) in blood and cerebrospinal fluid (CSF).</p><p><strong>Material and methods: </strong>The concentrations of 93 potential biomarkers in plasma and CSF were studied in patients with AD at various stages (<i>n</i>=53) and independently in the group at the predementia stage (<i>n</i>=15).</p><p><strong>Results: </strong>Statistically significant correlations of various directions (<i>p</i>≤0.05) were found between the coefficients characterizing the amyloidosis and neurodegeneration (Aβ-42/Aβ-40, phTau181/Aβ-42, phTau181/oTau, oTau/Aβ-42) with markers associated with neuroinflammation, vascular disorders, angiogenesis, neuroimaging changes, and neuropsychological indicators. Previous studies of markers associated with inflammation in CSF in AD patients have shown mixed results, and no markers have been introduced into clinical practice so far. Many biomarkers associated with two classical pathogenetic links and other pathophysiological processes have been identified.</p><p><strong>Conclusion: </strong>Coefficients reflecting two main pathogenetic processes in CSF of AD patients (Aβ-42/Aβ-40, phTau181/Aβ-42, phTau181/oTau, oTau/Aβ-42) are the most informative for verifying two main links in the disease pathogenesis-amyloidogenesis and neurodegeneration. In the group of patients with amnestic mild cognitive impairment (aMCI), statistically significant relationships of cytokines associated with neuroinflammation, growth factors, and complement system protein with coefficients of amyloidosis and neurodegeneration in CSF, as well as PET, MRI, and neuropsychological tests were shown; therefore, these indicators can also be considered as potential diagnostic biomarkers of early stages and possible predictors of MCI conversion to dementia. Such markers as GFAP, apolipoprotein A1, GDF-15, IFN-γ, IL-5, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17, VEGF, and complement C3 should be considered as objects for further research as biomarkers for early diagnosis.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"125 4. Vyp. 2","pages":"43-53"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144152436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Features of brain involvement in patients with type 1 neurofibromatosis in the Republic of Bashkortostan].","authors":"R N Mustafin","doi":"10.17116/jnevro202512505177","DOIUrl":"https://doi.org/10.17116/jnevro202512505177","url":null,"abstract":"<p><strong>The objective of the study is: </strong>To determine the features of brain damage in patients with type 1 neurofibromatosis (NF1) in the Republic of Bashkortostan (RB).</p><p><strong>Material and methods: </strong>The clinical presentation of NF1 in patients in the Republic of Bashkortostan with brain damage, as well as the accessibility of specialized care were analyzed. The mean age was 30.6 years (8 months to 85 years). The ratio of females to males was 1:1. The ethnic composition of patients corresponds to the general population in the republic.</p><p><strong>Results: </strong>The prevalence of NF1 in the republic was 13.5 per 100.000 population. Cognitive deficits have been identified in 15% of NF1 patients (of which 75% were severe); 6% have optic gliomas, 5% have brain cysts, 4.23% have hydrocephalus, 3.86% have brain tumors, and 3.7% have epilepsy.</p><p><strong>Discussion: </strong>Learning difficulties and optic nerve gliomas were significantly rarer compared to the worldwide data. Possible reasons for the lower detectability of cognitive deficits may be doctors' insufficient alertness, a shortage of psychologists and neurologists, and social factors. There is no data on the psychological disorders in NF1 patients in the republic; however, a high prevalence of brain cysts was revealed. Optic nerve gliomas, epilepsy, and short stature in patients with cognitive deficits are statistically significantly more common. The analysis of the availability of specialized care showed a sufficient number of geneticists in the country and difficulties in timely using instrumental research methods (MRI) and consultations with neurologists, ophthalmologists, psychologists, and psychotherapists.</p><p><strong>Conclusion: </strong>The results indicate the need for accessible brain MRI and consultations with neurologists, psychologists, and psychotherapists for all NF1 patients in the republic to detect brain lesions and psychological disorders in a timely manner. The detection of brain cysts in 5% of patients may be specific to the NF1 region.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"125 5","pages":"77-83"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144210386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The possibility of using neurotropic therapy in patients with persistent postural-perceptual dizziness].","authors":"N A Ivonina, K B Petrov","doi":"10.17116/jnevro202512505189","DOIUrl":"https://doi.org/10.17116/jnevro202512505189","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;The purpose of this study is to study the effectiveness of the use of Cortexin and Recognan drugs in complex therapy in patients with persistent postural perceptual dizziness (PPPD).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Material and methods: &lt;/strong&gt;60 patients with PPPD were included in the observational study. Patients in the study group received escitalopram at a dose of 10 mg in basic therapy for 6 months. After 2 weeks from the start of basic therapy, the patients were divided into 3 groups of 20 patients each. Patients of the 1&lt;sup&gt;st&lt;/sup&gt; group were prescribed Cortexin 10 mg intramuscularly, 1 time per day for 10 days, the 2&lt;sup&gt;nd&lt;/sup&gt; group - Cortexin 10 mg intramuscularly, 1 time per day for 10 days, and the drug Recognan 1000 mg 1 sachet 1 time per day for 10 days. Patients of the 3d group received basic therapy Escitalopram 10 mg once a day. The patients' condition was assessed three times: before the start of therapy, after the end of the 10-day course of therapy, and a follow-up examination 2 months after the end of the course of therapy while continuing to take the SSRI drug. To study the severity of dizziness and balance disorders, the VSS-ST scale was used - a short form of the scale of symptoms of dizziness, which has two subscales - the Vestibular Balance Scale (VSS-ST-V) and the Vegetative Anxiety Scale (VSS-ST-A). To assess sleep disorders in the study group, testing was performed on the Insomnia Severity Scale. Anxiety was assessed on a GAD-7 Scale (Generalized Anxiety Disorders -7). In addition, the Anxiety Sensitivity Index -3 Anxiety Sensitivity Index-3 (ASI -3) was determined in patients.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Prior to therapy, high scores in the VSS-ST-V subscale (average score 27.15±2.83) and moderate manifestations in the VSS-ST-A subscale (average score 16.05±2.35) were detected in all patients. Clinically significant insomnia was detected in patients of all groups (mean score 18.3±1.76). High indicators of anxiety, as well as the index of anxiety sensitization, were revealed. The second study of patients showed a significant improvement in vestibular balance, a decrease in anxiety and sleep disorders, especially in patients receiving complex therapy. In the third test, patients receiving Cortexin and Recognan showed statistically significant positive changes in almost all indicators: VSS-ST-V and VSS-ST-A subscales (average score 27.15±2.83), insomnia, and ASI-3. This reflects the fact that for the relief of anxiety disorder associated with dizziness, it is necessary a sufficient amount of time from the start of complex therapy requires activation of the processes of central vestibular compensation.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;It should be noted that the positive results of this study can be considered a decrease in the severity and severity of symptoms of dizziness, anxiety, insomnia, and a decrease in the index of anxiety sensitization in patients of all observation groups. Patients rec","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"125 5","pages":"89-94"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144210396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Cerebrolysin and the optimal timing of anticoagulation resumption in stroke: combined post hoc survival analysis of the CEREHETIS trial].","authors":"M N Kalinin, D R Khasanova","doi":"10.17116/jnevro202512503277","DOIUrl":"10.17116/jnevro202512503277","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effect of Cerebrolysin on hazard dynamics of hemorrhagic transformation (HT) and identify optimal anticoagulation therapy (AT) resumption timing in stroke patients, stratified by the Hemorrhagic Transformation Index (HTI).</p><p><strong>Material and methods: </strong>A post hoc survival analysis of the CEREHETIS trial (ISRCTN87656744) included patients with middle cerebral artery infarctions. The intervention group (IG, <i>n</i>=91) received Cerebrolysin with intravenous thrombolysis (IVT) and standard care, while the control group (CG, <i>n</i>=147) received IVT and standard care alone. Additionally, a validation cohort (VC, <i>n</i>=248) from an observational study was analyzed. Patients were stratified into low-risk (HT=0), high-risk (HTI=1-4), and very-high-risk (HTI=5-8, VC only) groups. Symptomatic HT and any HT within 14 days post-stroke were defined as failure events. Hazard dynamics were modeled using a Gompertz parametric survival approach, with a hazard threshold (0.6% per day) estimating safe AT resumption timing.</p><p><strong>Results: </strong>Cerebrolysin significantly reduced risk of symptomatic HT (HR 0.245; 95% CI 0.072-0.837; <i>p</i>=0.02) and any HT (HR 0.543; 95% CI 0.297-0.991; <i>p</i>=0.032). The compounding effect peaked on day 1 and persisted through days 7-10 in very-high-risk patients (HTI=5-8). In high-risk patients (HTI=1-4), Cerebrolysin mitigated the compounding effect and reduced hazard levels to the threshold by day 2, compared to days 3-5 in the CG and VC. The hazardous period extended to day 10 in HTI=5-8. In low-risk patients (HTI=0), hazard levels remained below the threshold from day 1, with no measurable impact of Cerebrolysin on HT.</p><p><strong>Conclusion: </strong>AT may be safely resumed within 48 h in low-risk patients (HTI=0), on days 3-5 in high-risk patients (HTI=1-4), and on day 10 in very-high-risk patients (HTI=5-8) without symptomatic HT. Cerebrolysin mitigates the compounding effect, reduces HT risk, and facilitates earlier, safer AT resumption in high-risk patients (HTI=1-4) by day 2 post-stroke, supporting its role in personalized stroke management.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"125 3. Vyp. 2","pages":"77-93"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Prediction of mortality in severe ischemic stroke during COVID-19 in patients with multiorgan dysfunction].","authors":"V I Ershov, A S Dobrynin, A A Golubkina","doi":"10.17116/jnevro2025125061120","DOIUrl":"https://doi.org/10.17116/jnevro2025125061120","url":null,"abstract":"<p><strong>Objective: </strong>To determine the prognostic value of multiorgan dysfunction (MOD) for the course and outcomes of severe ischemic stroke (IS) that occurred during the new coronavirus infection COVID-19.</p><p><strong>Material and methods: </strong>A retrospective study included 110 patients with severe IS with 16 or more NIHSS points (National Institutes of Health Stroke Scale). The MOD severity on days 1 and 5 of hospitalization was assessed using the SAPS II score. The relationship between probable mortality and the severity of multiorgan dysfunction by SAPS-II in atherothrombotic and cardioembolic subtypes combined with COVID-19 was modeled. In order to determine the predictive significance of the model, a ROC analysis was performed.</p><p><strong>Results: </strong>Non-survivors had higher SAPS II MOD severity on Day 1, with 33 (27; 39) points and 23 (20; 27) points, respectively (<i>p</i>=0.038). With the development of severe IS combined with COVID-19 complicated by MOD, an unfavorable outcome is significantly more often observed in the cardioembolic subtype compared with the atherothrombotic subtype (68.23% and 31.76%, respectively, <i>p</i>=0.045). The comparative regression analysis showed that the mortality probability was significantly higher in cardioembolic stroke for patients with MOD severity of 10 to 41 points on the SAPS II score (<i>p</i>=0.043). The results of the ROC analysis showed a high prognostic value of the SAPS II score for predicting death in severe IS that occurred during COVID-19 in patients with MOD. Also, in the cardioembolic subtype, the prognostic value of the SAPS II score is significantly higher than in the atherothrombotic subtype.</p><p><strong>Conclusion: </strong>MOD is a key mortality-associated indicator in patients with severe IS and concomitant COVID-19. The mortality risk is significantly higher in patients with cardioembolic IS subtype.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"125 6","pages":"120-127"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144512843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Structural features of the brain in amnestic mild cognitive impairment and their correlation with mild behavioral impairment].","authors":"N S Cherkasov, A S Tomyshev, I S Lebedeva, E G Abdullina, O V Bozhko, S I Gavrilova, I V Kolykhalov","doi":"10.17116/jnevro2025125061112","DOIUrl":"10.17116/jnevro2025125061112","url":null,"abstract":"<p><strong>Objective: </strong>To determine the structural features of the brain in elderly patients with amnestic syndrome of mild cognitive decline (aMCI) and to identify correlations of these features with mild behavioral disorders.</p><p><strong>Material and methods: </strong>Fifty-three patients with aMCI (age 73.0±8.5 years, 9 males) and 34 mentally healthy subjects (66.8±9.6 years, 4 males) were examined. Cognitive status was assessed according to the Montreal Cognitive Assessment (MoCA) scale, and the severity of mild behavioral impairment was assessed according to the Mild Behavioral Impairment Checklist (MBI-C). Structural MRI images were obtained using a 3T Philips Ingenia. Cortical gray matter thickness, volumes of subcortical structures, and their correlation with MBI-C and MoCA scores were analyzed.</p><p><strong>Results: </strong>In patients with aMCI, a smaller cortical thickness was found in the left superior frontal gyrus and right precuneus (<i>p<</i>0.05), as well as negative correlations of these indicators with MBI-C scores. Also, this group showed smaller volumes of the amygdala and hippocampus of the left hemisphere (<i>p<</i>0.05) and a positive correlation between the volume of the left amygdala and MoCA scores.</p><p><strong>Conclusion: </strong>The identified changes in structural MRI indicators and their correlation with neuropsychiatric and neurocognitive symptoms reflect the complex nature of the brain substrate of cognitive and behavioral impairment in aMCI. The results indicate the need for further search for clinically significant phenotypes in patients with aMCI, including those associated with an increased risk of Alzheimer's disease.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"125 6","pages":"112-119"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144512845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}